120 related articles for article (PubMed ID: 31962100)
21. Loss of thymic function promotes EAE relapse in anti-CD52-treated mice.
Adegoke AO; Lin J; Anderson CC
Curr Res Immunol; 2022; 3():37-41. PubMed ID: 35496821
[TBL] [Abstract][Full Text] [Related]
22. Connexin 30 Deficiency Attenuates Chronic but Not Acute Phases of Experimental Autoimmune Encephalomyelitis Through Induction of Neuroprotective Microglia.
Fang M; Yamasaki R; Li G; Masaki K; Yamaguchi H; Fujita A; Isobe N; Kira JI
Front Immunol; 2018; 9():2588. PubMed ID: 30464764
[TBL] [Abstract][Full Text] [Related]
23. Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis.
Rao SP; Sancho J; Campos-Rivera J; Boutin PM; Severy PB; Weeden T; Shankara S; Roberts BL; Kaplan JM
PLoS One; 2012; 7(6):e39416. PubMed ID: 22761788
[TBL] [Abstract][Full Text] [Related]
24. The immunological function of CD52 and its targeting in organ transplantation.
Zhao Y; Su H; Shen X; Du J; Zhang X; Zhao Y
Inflamm Res; 2017 Jul; 66(7):571-578. PubMed ID: 28283679
[TBL] [Abstract][Full Text] [Related]
25. High Mutation Frequency of the
Loeff FC; Falkenburg JHF; Hageman L; Huisman W; Veld SAJ; van Egmond HME; van de Meent M; von dem Borne PA; Veelken H; Halkes CJM; Jedema I
J Immunol; 2018 Mar; 200(6):2199-2208. PubMed ID: 29427418
[TBL] [Abstract][Full Text] [Related]
26. CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma.
Cruz RI; Hernandez-Ilizaliturri FJ; Olejniczak S; Deeb G; Knight J; Wallace P; Thurberg BL; Kennedy W; Czuczman MS
Leuk Lymphoma; 2007 Dec; 48(12):2424-36. PubMed ID: 18067019
[TBL] [Abstract][Full Text] [Related]
27. Immunophenotype Expression Change From CD52+ to CD52- on Erythrodermic Peripheral T-cell Lymphoma, Not Otherwise Specified After Treatment With Alemtuzumab.
Dhandha MM; Sufficool KE; Vidal CI; Robbins KJ; Fesler MJ; Batanian JR; Hurley MY
Am J Dermatopathol; 2018 Jul; 40(7):547-550. PubMed ID: 28937435
[No Abstract] [Full Text] [Related]
28. IL-21 Biased Alemtuzumab Induced Chronic Antibody-Mediated Rejection Is Reversed by LFA-1 Costimulation Blockade.
Kwun J; Park J; Yi JS; Farris AB; Kirk AD; Knechtle SJ
Front Immunol; 2018; 9():2323. PubMed ID: 30374350
[TBL] [Abstract][Full Text] [Related]
29. CD52 expression in T-cell large granular lymphocyte leukemia--implications for treatment with alemtuzumab.
Osuji N; Del Giudice I; Matutes E; Morilla A; Owusu-Ankomah K; Morilla R; Dunlop A; Catovksy D
Leuk Lymphoma; 2005 May; 46(5):723-7. PubMed ID: 16019510
[TBL] [Abstract][Full Text] [Related]
30. Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis.
Gentile A; Musella A; Bullitta S; Fresegna D; De Vito F; Fantozzi R; Piras E; Gargano F; Borsellino G; Battistini L; Schubart A; Mandolesi G; Centonze D
J Neuroinflammation; 2016 Aug; 13(1):207. PubMed ID: 27566665
[TBL] [Abstract][Full Text] [Related]
31. Insights into the Mechanisms of the Therapeutic Efficacy of Alemtuzumab in Multiple Sclerosis.
Freedman MS; Kaplan JM; Markovic-Plese S
J Clin Cell Immunol; 2013 Jul; 4(4):. PubMed ID: 24363961
[TBL] [Abstract][Full Text] [Related]
32. Alemtuzumab for the treatment of multiple sclerosis.
Evan JR; Bozkurt SB; Thomas NC; Bagnato F
Expert Opin Biol Ther; 2018 Mar; 18(3):323-334. PubMed ID: 29309202
[TBL] [Abstract][Full Text] [Related]
33. Immune status following alemtuzumab treatment in human CD52 transgenic mice.
Turner MJ; Lamorte MJ; Chretien N; Havari E; Roberts BL; Kaplan JM; Siders WM
J Neuroimmunol; 2013 Aug; 261(1-2):29-36. PubMed ID: 23759318
[TBL] [Abstract][Full Text] [Related]
34. Alemtuzumab scFv fragments and CD52 interaction study through molecular dynamics simulation and binding free energy.
Frota NF; Rebouças AS; Fuzo CA; Lourenzoni MR
J Mol Graph Model; 2021 Sep; 107():107949. PubMed ID: 34089985
[TBL] [Abstract][Full Text] [Related]
35. Neuronal injury in chronic CNS inflammation.
Zindler E; Zipp F
Best Pract Res Clin Anaesthesiol; 2010 Dec; 24(4):551-62. PubMed ID: 21619866
[TBL] [Abstract][Full Text] [Related]
36. Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond.
Ruck T; Bittner S; Wiendl H; Meuth SG
Int J Mol Sci; 2015 Jul; 16(7):16414-39. PubMed ID: 26204829
[TBL] [Abstract][Full Text] [Related]
37. Microglial and astroglial reactions to inflammatory lesions of experimental autoimmune encephalomyelitis in the rat central nervous system.
Matsumoto Y; Ohmori K; Fujiwara M
J Neuroimmunol; 1992 Mar; 37(1-2):23-33. PubMed ID: 1372328
[TBL] [Abstract][Full Text] [Related]
38. The CD45 tyrosine phosphatase regulates Campath-1H (CD52)-induced TCR-dependent signal transduction in human T cells.
Hederer RA; Guntermann C; Miller N; Nagy P; Szollosi J; Damjanovich S; Hale G; Alexander DR
Int Immunol; 2000 Apr; 12(4):505-16. PubMed ID: 10744652
[TBL] [Abstract][Full Text] [Related]
39. Interleukin-15 augments NK cell-mediated ADCC of alemtuzumab in patients with CD52+ T-cell malignancies.
Miljkovic MD; Dubois SP; Müller JR; Bryant B; Ma E; Conlon KC; Waldmann TA
Blood Adv; 2023 Feb; 7(3):384-394. PubMed ID: 35475910
[TBL] [Abstract][Full Text] [Related]
40. Anti-CD52 Therapy for Multiple Sclerosis: An Update in the COVID Era.
Kasarello K; Mirowska-Guzel D
Immunotargets Ther; 2021; 10():237-246. PubMed ID: 34268256
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
